In March 1919, the National Epidemic Prevention Bureau was officially established in Beijing, and was set at the former site of the Office of Divine Music inside the Temple of Heaven. It combines epidemic prevention with the research, development and production of biological products such as vaccines, representing the birthplace of biological products in China.

Tang Feifan isolated trachoma virus, becoming the first Chinese in the world to discover an important pathogen

Zhang Yihao, as a member of the Committee to Certification of Smallpox Eradication, signed the Global Smallpox Eradication Certificate

In 1989, BIBP introduced the industrialized production technology of recombinant yeast hepatitis B vaccine from Merck & Co. which greatly improved the supply and guarantee the capacity of hepatitis B vaccine in China. Clinical observation of recombinant yeast produced by Merck's production line has proved that the effect of blocking mother-to-child transmission of hepatitis B is stronger than other hepatitis B vaccines.

The recombinant yeast genetically engineered hepatitis B vaccine was successfully transferred. Academician Zhao Kai held the first genetically engineered hepatitis B vaccine.

BIBP took the lead in establishing the large-scale P3 high level biosafety production facility for COVID-19 vaccine

In 2020, the World's First Inactivated COVID-19 Vaccine was MarketedThe .COVID-19 epidemic is the most widespread global epidemic that has been encountered by human beings in the past 100 years. The CPC Central Committee and the State Council have attached great importance to the research, development and production of vaccines. Under the guidance and strong support of leaders at all levels, the BIBP’s COVID-19 Vaccine R&D team has successfully developed and launched the world's first inactivated COVID-19 vaccine.

On April 1, 2021, the Hungary National Institute of Pharmacy and Nutrition officially issued the EU GMP certificate for the Inactivated COVID-19 Vaccine (Vero Cell) to BIBP. This is the first vaccine product approved for use in the EU and obtained GMP certification in China's history, marking a new step for China's COVID-19 vaccine to become a global public product.

On May 7, 2021, BIBP’s COVID-19 vaccine was approved by the WHO “Emergency Use Listing (EUL)”, it is the first COVID-19 vaccine from an non-western country to be approved by the WHO. This has reinforced the Chinese power to the global fight against the COVID-19 epidemic, also to the building of human health community.